The worldwide pulmonary arterial hypertension market was worth USD 5.3 billion in 2020, and it is predicted to increase at a CAGR of 4.9 percent from 2021 to 2028. The market is predicted to rise significantly during the forecast period due to an increase in the prevalence of PAH (pulmonary arterial hypertension), a growing elderly population, and increased government assistance for the development of orphan medications. PAH instances are estimated to be in the 100,000 to 200,000 range every year. However, the prevalence of PAH has increased in recent years due to a variety of causes, including sedentary lifestyle, an increase in the incidence of HIV, an increase in smoking and alcohol/tobacco intake, and other idiopathic disorders. Patients with pulmonary arterial hypertension are at a greater risk of contracting COVID-19.
According to the American College of Cardiology, the incidence rate of COVID-19 infection in PAH patients was 2.1 instances per 1,000 patients as of August 2020. This boosted the need for PAH medications for the treatment of COVID-19 infection. This demand had a favorable influence on market growth.
To acquire a competitive advantage in the industry, market participants are spending in product launches and collaborations. For example, United Therapeutics commercialized a Remunity pump for Remodulin to treat pulmonary arterial hypertension in February 2021. This device is tiny, compact, and preloaded with medicine, and it outperforms conventional subcutaneous pump options. This is expected to have a beneficial impact on overall market growth throughout the forecast period.